Thrivent Financial for Lutherans
DNTH icon

Thrivent Financial for Lutherans’s Dianthus Therapeutics DNTH Stock Holding History

Thrivent Financial for Lutherans’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-8,087
Closed -$47K – 2452
2022
Q4 		$47K Buy
+8,087
New +$143K ﹤0.01% 2395

Other funds holding DNTH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
TG
TCW Group Los Angeles, California $13.3B AUM 34.44% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Thrivent Financial for Lutherans's DNTH Position: Q1 2023 in Review

Thrivent Financial for Lutherans sold out of Dianthus Therapeutics (DNTH) in Q1 2023, closing a stake of 8,087 shares — an estimated $47K sold.

Thrivent Financial for Lutherans first reported a position in DNTH in Q4 2022 and held it in 1 quarter. The position peaked at $47K in Q4 2022. 51 funds tracked by Wall St. Rank hold DNTH as of Q1 2023.

  • Thrivent Financial for Lutherans reported no remaining Dianthus Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 8,087 Dianthus Therapeutics shares in Q1 2023, an estimated $47K.
  • Thrivent Financial for Lutherans first reported a position in Dianthus Therapeutics in Q4 2022 and held it in 1 quarter.
  • Thrivent Financial for Lutherans's Dianthus Therapeutics position peaked at $47K in Q4 2022.
  • 51 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2023.

Based on Thrivent Financial for Lutherans's 13F filing for Q1 2023, filed 17 May 2023.